AnaptysBio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ANAB Nasdaq 8731 https://www.anaptysbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AnaptysBio Inc

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial - Mar 27th, 2023 10:50 pm
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates - Mar 1st, 2023 10:45 pm
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update - Mar 1st, 2023 9:05 pm
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference - Feb 27th, 2023 9:05 pm
AnaptysBio Announces Stock Repurchase Plan - Jan 13th, 2023 2:00 pm
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies - Jan 5th, 2023 9:05 pm
The past five years for AnaptysBio (NASDAQ:ANAB) investors has not been profitable - Dec 22nd, 2022 2:33 pm
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer - Dec 2nd, 2022 2:00 pm
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference - Nov 21st, 2022 6:56 pm
AnaptysBio Third Quarter 2022 Earnings: Misses Expectations - Nov 11th, 2022 10:19 am
AnaptysBio to Participate in Upcoming November Investor Conferences - Nov 9th, 2022 7:10 pm
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates - Nov 8th, 2022 10:55 pm
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update - Nov 8th, 2022 9:05 pm
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation - Oct 25th, 2022 10:28 am
AnaptysBio, Inc. (ANAB) Just Flashed Golden Cross Signal: Do You Buy? - Oct 13th, 2022 1:55 pm
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal - Oct 6th, 2022 3:02 pm
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial - Oct 5th, 2022 3:31 pm
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials - Oct 5th, 2022 1:00 pm
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors - Sep 26th, 2022 12:00 pm
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround - Sep 19th, 2022 6:02 pm